Laurus Labs Limited (NSE: LAURUSLABS, BSE: 540222) shares closed at ₹1,017.15 on Friday, up 1.21% following the release of its third-quarter financial results. The pharmaceutical manufacturer’s shares reached an intraday high of ₹1,032 before settling higher for the session.
Market Capitalization
The company’s market capitalization stands at approximately ₹549.17 billion based on today’s closing price.
Latest Quarterly Results
For the quarter ended December 31, 2025, Laurus Labs reported consolidated revenue from operations of ₹17.78 billion, a 25.7% increase compared with ₹14.15 billion in the same period last year. Net profit for the quarter rose 174% to ₹2.52 billion, up from ₹923 million a year ago.
Operating performance by segment:
- Generics (API & FDF): Revenue grew 37% year-on-year to ₹13.27 billion.
- Synthesis (CDMO): Revenue increased 2% to ₹4.08 billion.
- Bio: Revenue for the period was ₹430 million.
- EBITDA: Reported at ₹4.85 billion, with margins expanding to 27.3% from 20.1% year-on-year.
Full-Year Results Context
For the nine months ended December 31, 2025, total revenue reached ₹50.01 billion, a 30% increase over the previous year. Nine-month EBITDA stood at ₹13.03 billion, representing a 104% increase. Net debt-to-EBITDA improved to 1.2x from 3.4x in the prior year, indicating a directional trend of deleveraging.
CHART — FINANCIAL TRENDS
Business & Operations Update
The company confirmed the operationalization of its high-potent API plant at Unit 2 in Visakhapatnam. In the animal health segment, commercial supplies have commenced following the completion of qualification batches. The company reported a 15% capital expenditure-to-sales ratio for the period, focused on its new manufacturing complex.
M&A or Strategic Moves
Laurus Labs increased its investment in KRKA Pharma India by ₹490 million, bringing the total joint venture investment to ₹1 billion. The company also executed a $2 million strategic investment in Aarvik Therapeutics to access antibody-drug conjugate (ADC) technology. Additionally, a further equity infusion was made into ImmunoACT to support the scaling of CAR-T cell therapy services.
Equity Analyst Commentary
Institutional research from Motilal Oswal and Kotak Institutional Equities noted the recovery in the ARV portfolio and CDMO project execution. Reports from BOB Capital Markets indicated that the Q3 results were ahead of consensus estimates for margins and net income.
Guidance & Outlook
Management stated that the company remains on track to deliver its stated operational growth for the full fiscal year. Key factors to watch include the continued ramp-up of the animal health division and the progression of the eight-year, $600 million investment plan for the Andhra Pradesh manufacturing hub.
Performance Summary
Laurus Labs shares closed 1.21% higher following a 174% increase in quarterly profit. Revenue grew 26% for the quarter and 30% for the nine-month period. Operational improvements were driven by the Generics and CDMO segments, alongside a reduction in the net debt-to-EBITDA ratio.